Health Economics›Thyroid cancer differentiated›Advanced or metastatic disease radioactive iodine-refractory

Advanced or metastatic disease radioactive iodine-refractory

Thyroid cancer differentiated · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 151 638	28d	~11.0 mo	—	~2	~R 303 276 PFS proxy · indirect	2
Sunitinib monotherapy Variant #01	—	R 33 433	42d	~8.3 mo	~32.4 mo	~2	~R 49 300 PFS proxy · indirect	36
Lenvatinib monotherapy Variant #01	—	R 27 935	28d	~21.1 mo	—	~2	~R 55 870 PFS proxy · indirect	2
Pazopanib monotherapy Variant #01	—	R 22 754	28d	~8.8 mo	~22.9 mo	~26	~R 591 593 PFS proxy · indirect	8
Sorafenib monotherapy Variant #04	—	R 16 002	28d	~10.8 mo	—	~2	~R 32 005 PFS proxy · indirect	1
Apatinib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	1
Placebo Partial	—	—	—	~4.7 mo	~29.9 mo	—	—	7
Vandetanib monotherapy Variant #01 Partial	—	—	28d	~10.6 mo	—	~2	—	2
Donafenib monotherapy Variant #01 Partial	—	—	28d	~12.9 mo	—	~2	—	1

9 of 9 regimens shown